Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-27T08:11:20.016Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical profiles and outcomes for Omani children with dilated cardiomyopathy seen in a regional referral hospital

Published online by Cambridge University Press:  01 April 2009

Olufemi Jaiyesimi  and
Mohamed Kasem
Olufemi Jaiyesimi*
Affiliation:
Department of Paediatrics, Regional Referral Hospital, Nizwa, Oman
Mohamed Kasem
Affiliation:
Department of Paediatrics, Regional Referral Hospital, Nizwa, Oman
*
Correspondence to: Professor Olufemi Jaiyesimi, PO Box 1241; Nizwa. Code 611. Sultanate of Oman. Tel/Fax:+968 25449 259; E-mail: efjay@omantel.net.om
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

To provide an account of paediatric dilated cardiomyopathy as seen in a region of Oman, analysing the data from 32 consecutive children who received care in our unit between January, 1999, and August, 2007.

Results

The patients, of whom 17 were male, were aged between 5 weeks and 8 years at presentation, with a median of 7 months. The disease was deemed to be myocarditis-induced in one-third, and idiopathic in half. Cardiac failure, seen in almost four-fifths, was the most frequent presenting feature. Correspondingly, the cardiothoracic ratios were increased, to a mean of 68% in 20 infants, and to 65% in 8 older children, and the left ventricular ejection fraction depressed, to a mean of 41%, in the 23 patients in whom it could be evaluated. Patients in cardiac failure received various combinations of diuretics, inotropes, and captopril. In addition, 6 received carvedilol, and 3 intravenous immunoglobulin. Death occurred in 2 patients shortly after admission, one left the hospital against medical advice, and the remaining 29 were followed-up for a mean of 37 months, with a range from 2 to 102 months. Recovery was noted in one-third of the patients, with one-quarter showing improvement but still requiring anti-failure medications. Slightly over two-fifths died. Of those with the idiopathic form, 40% died, with death occurring in 46% of those deemed to have myocarditis-induced disease, in half of those presenting in infancy, and in 57% of those who presented in cardiac failure.

Conclusion

Dilated cardiomyopathy was often severe in our patients, albeit that the cause was frequently uncertain, and the response to standard anti-failure treatment unsatisfactory. Efforts should be intensified for unravelling its aetiology and improving medical treatment.

Keywords

Heart muscle diseasedilated left heart
Type
Original Article
Information
Cardiology in the Young , Volume 19 , Issue 2 , April 2009 , pp. 145 - 151
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.WHO. Report of the 1995 WHO/ISFC Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93: 841–842.CrossRefGoogle Scholar
2.Griffin, ML, Hernandez, A, Martin, TC, et al. Dilated cardiomyopathy in infants and children. J Am Coll Cardiol 1988; 11: 139–144.CrossRefGoogle ScholarPubMed
3.Akagi, T, Benson, LN, Lightfoot, NE, Chin, K, Wilson, G, Freedom, RM. Natural history of dilated cardiomyopathy in children. Amer Heart J 1991; 121: 1502–1506.CrossRefGoogle ScholarPubMed
4.Burch, M, Siddiqi, SA, Celermajer, DS, Scott, C, Bull, C, Deanfield, JE. Dilated cardiomyopathy in children: determinants of outcome. Br Heart J 1994; 72: 245–250.CrossRefGoogle ScholarPubMed
5.Nugent, AW, Daubeney, PEF, Chondros, P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Eng J Med 2003; 348: 1634–1646.Google Scholar
6.Gagliardi, MG, Bevilacqua, M, Bassano, C, et al. Long term follow up of children with myocarditis treated by immunosuppression and of children with dilated cardiomyopathy. Heart 2004; 90: 1167–1171.Google Scholar
7.Weng, K-P, Lin, C-C, Huang, S-H, Hsieh, K-S. Idiopathic dilated cardiomyopathy in children: a single medical center’s experience. J Chin Med Assoc 2005; 68: 368–372.Google Scholar
8.American Heart Association. Contemporary definitions and classification of the cardiomyopathies. Circulation 2006; 113: 1807–1816.CrossRefGoogle Scholar
9.Arola, A, Tuominen, J, Ruuskanen, O, Jokinen, E. Idiopathic dilated cardiomyopathy in children: prognostic indicators and outcome. Pediatrics 1998; 101: 369–376.Google Scholar
10.Venugopalan, P, Agarwal, AK, Akinbami, FO, El Nour, IB, Subramanyan, R. Improved prognosis of heart failure due to idiopathic dilated cardiomyopathy in children. Int J Cardiol 1998; 65: 125–128.CrossRefGoogle ScholarPubMed
11.Seliem, MA, Mansara, KB, Palileo, MAE, Xiaobu, YE, Zhang, Z, Benson, DW. Evidence for autosomal recessive inheritance of infantile dilated cardiomyopathy: studies from the Eastern Province of Saudi Arabia. Pediatr Res 2000; 48: 770–775.CrossRefGoogle ScholarPubMed
12.Park, MK. The Pediatric Cardiology Handbook. Mosby Inc, Philadelphia, 1997, p 54.Google Scholar
13.Ciszewski, A, Bilinska, ZT, Lubiszewska, B, et al. Dilated cardiomyopathy in children: clinical course and prognosis. Pediatr Cardiol 1994; 15: 121–126.Google Scholar
14.Nogueira, G, Pinto, FF, Paixao, A, Kaku, S. Idiopathic dilated cardiomyopathy: clinical profile and prognostic determinants. Rew Port Cardiol 2000; 19: 191–200.Google ScholarPubMed
15.Venugopalan, P, Houston, AB, Agarwal, AK. The outcome of dilated cardiomyopathy and myocarditis in children from the west of Scotland. Int J Cardiol 2001; 78: 135–141.CrossRefGoogle ScholarPubMed
16.Azevedo, VM, Albanesi Filho, FM, Santos, MA, Castier, MB, Tura, BR. Prognostic values of chest roentgenograms in children with dilated cardiomyopathy. J Pediatr (Rio J) 2004; 80: 71–76.CrossRefGoogle ScholarPubMed
17.Tsirka, AE, Trinkaus, K, Chen, S-C, et al. Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. J Am Coll Cardiol 2004; 44: 391–397.Google Scholar
18.Daubeney, PEF, Nugent, AW, Chondros, P, et al. Clinical features and outcomes of childhood dilated cardiomyopathy. Circulation 2006; 114: 2671–2678.CrossRefGoogle ScholarPubMed
19.Towbin, JA, Lowe, AM, Colan, SD, et al. Incidence, causes and outcomes of dilated cardiomyopathy in children. JAMA 2006; 296: 1867–1876.Google Scholar
20.Weintraub, RG, Nugent, AW, Daubeney, EF. Pediatric cardiomyopathy: the Australian experience. Prog Pediatr Cardiol 2007; 23: 17–24.Google Scholar
21.Lewis, AB, Chabot, M. Outcome of infants and children with dilated cardiomyopathy. Am J Cardiol 1991; 68: 365–369.CrossRefGoogle ScholarPubMed
22.Wiles, HB, McArthur, PD, Taylor, AB. Prognostic features of children with idiopathic dilated cardiomyopathy. Am J Cardiol 1991; 68: 1372–1376.Google Scholar
23.Colan, SD. Cardiomyopathies. In: Kean JF, Lock JE, Fyler DC (eds). Nadas Pediatric Cardiology, 2nd ed. Saunders Elsevier, Philadelphia, 2006, pp 415–458.Google Scholar
24.Aretz, HT. Myocarditis: the Dallas criteria. Human Pathol 1987; 18: 619–624.Google Scholar
25.Baughman, KL. Diagnosis of myocarditis. Death of Dallas criteria. Circulation 2006; 113: 593–595.CrossRefGoogle ScholarPubMed
26.Burch, M. Immune suppressive treatment in paediatric myocarditis: still awaiting the evidence. Heart 2004; 90: 1103–1104.Google Scholar
27.McElhinney, DB, Colan, SD, Moran, AM, et al. Recombinant human growth hormone treatment for dilated cardiomyopathy in children. Pediatrics 2004; 114: e452–e458.CrossRefGoogle ScholarPubMed
28.Le Corvoisier, P, Hittinger, L, Chanson, P, Montagne, O, Macquin-Mavier, I, Maison, P. Cardiac effects of growth hormone treatment in chronic heart failure. J Clin Endocrinol Metab 2007; 92: 180–185.Google Scholar
29.Kaufman, BD, Shaddy, RE. Beta-adrenergic blockade and pediatric dilated cardiomyopathy. Prog Pediatr Cardiol 2007; 24: 51–57.CrossRefGoogle Scholar
30.Shaddy, RE, Boucek, MM, Hsu, DT, et al. Carvedilol for children and adolescents with heart failure. JAMA 2007; 298: 1171–1179.CrossRefGoogle ScholarPubMed